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Abstract
Erythroidl eukemia is a heterogeneous disease with very poor prognosis. It may arise de novo, secondary to
myelodysplastic syndrome, blast crisis phase of chronic myeloid leukemia, or after cytotoxic therapy of acute
myeloid leukemia. The current mainstream treatment of erythroleukemia is cytarabine and anthracyclin-based
chemotherapy or bone marrow transplantation. In the current study we found that cytarabine or inhibition of the
DNA-damage-activated protein kinase, ATM, induce G2/M arrest and sensitised K562 erythro leukemia cells to
tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Arresting cells in G2/M with microtubule-disrupting
drugs also enhanced TRAIL-sensitivity. Synchronisation or separation of the leukemia cells in different stages of the
cell cycle by elutriation confirmed that the cells in G1 and G2/M were sensitive to TRAIL. Interestingly, this sensitivity
was associated with cell cycle-dependent oscillation of cFLIP expression. In summary, we found that combination of
cytostatic drugs with TRAIL can be an effective treatment for erythroid leukemia.
Keywords: TRAIL; Apoptosis; Combination therapy; DNA damage
response; Cell cycle; Erythroid leukemia
Introduction
TNF-related apoptosis inducing ligand (TRAIL/APO2L) is a death
ligand member of the TNF cytokine super family that interacts with
five different receptors, two of which can initiate apoptosis (death
receptors DR4 and DR5), whereas the other three are regulatory or
decoy receptors (DcR1, DcR2 and osteoprotegerin (OPG)). Binding of
TRAIL to DR4 or DR5 results in receptor activation followed by
sequential recruitment of the adaptor protein Fas-associated death
domain (FADD) and pro-caspase-8, thus forming the death-inducing
signalling complex (DISC). At the DISC, pro-caspase-8 is auto
activated and initiates a caspase cascade resulting in dismantling of
cellular components and consequent cell death [1]. TRAIL is highly
selective to tumour cells and unlike many other apoptotic pathways,
the it is not affected by p53-deficiency [2]. Therefore there is
significant interest in TRAIL as a potential anti-cancer therapeutic.
Acute erythroidleukemia (AEL) is a rare form of acute myeloid
leukemia (AML) with generally poor prognosis. AEL is a
heterogeneous disease often driven by highly undifferentiated
myelogenic progenitor cells characterised by genetic instability and
poor prognosis with the erythroidleukemia (pEL) subtype having a
patient median survival of 3 ± 3.6 months [3].
The mainstream therapy for erythroid leukemia is either bone
marrow transplantation or genotoxic drug therapy (cytarabine/
daunorubicin combination). Cytarabine (araC) competes with cytidine
for incorporation into the DNA leading to inhibition of DNA
polymerases and consequent disruption of DNA synthesis,
termination of chain elongation that causes DNA damage [4].
The generally low sensitivity of leukemic cells to TRAIL makes it a
less attractive therapeutic for these cancers [5]. Recent studies however
identified drug combination strategies that could potently sensitize
TRAIL-resistant tumours [6]. Additionally, a recent study on acute
lymphocytic leukemia has shown that the undifferentiated leukemia-
initiating cell (LIC) population is sensitive to TRAIL and tumour
extracts from TRAIL-treated xenografts fail to re-establish the tumour
when transplanted into a new animal [7] highlighting the possible
potential of TRAIL for targeting the undifferentiated cells driving
erythroid leukemia.
Based on these findings the aim of the current project was to test
whether a TRAIL-based therapy is able to eradicate erythroid leukemia
cells. We found that K562 erythroleukemia cells are partially sensitive
to TRAIL and araC and TRAIL act synergistically. Furthermore, we
found that TRAIL sensitivity is linked to normal cell cycle progression
as cells in early G1 or G2/M phase isolated by elutriation displayed
higher TRAIL-sensitivity, which correlated with a cell cycle-
dependent, oscillating expression of the anti-apoptotic protein cFLIP.
Arresting the cells in G2/M by either araC, inhibition of ATM or
microtubule disruption further increased TRAIL-sensitivity. In
conclusion, these results indicate that arresting erythroid leukemia
cells in G1 or G2/M using cytostatic or genotoxic drugs can render
them sensitive to TRAIL offering a potential novel treatment avenue.
Materials and Methods
Cellculture and treatments
The K562 erythroleukemia cell line derived from blast crisis chronic
myelogenous leukemia and positive for Bcr-Abl(CML)(ATCC #
CCL-243™) [8], was cultured in RPMI 1640 medium supplemented
with 10% foetal bovine serum, 2 mM glutamine, 1 mM pyruvate, 50
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U/ml penicillin and 50 μM streptomycin (all from Sigma) and
maintained at 37°C, 5% CO2 in a humidified incubator.
Cells were seeded at 2x105 cells/ml in 24-well plates 24 h before
treatment. Cytarabine (araC) (C1768-Sigma) was resuspended in
water at 100 mM and used at indicated concentrations for individual
experiments. TRAIL was produced according to [9]. Inhibitors of
DNA-PK (NU7441), ATM (KU55933) and Chk1 (UCN-01) were
purchased from Axum, BioConmed and Sigma, respectively.
Inhibitors were resuspended in DMSO and were used at the following
concentrations: 10 µM for NU-7441, 10 μM for KU-55933 and 100 nM
for UCN-01. Control cells were treated with equivalent volumes of
vehicle.
Annexin V staining
1x105 cells collected by centrifugation, resuspended in 50 μl
calcium buffer (10 mM HEPES pH7.5, 140 mM NaCl, 2.5 mM CaCl2)
containing 0.5 μl Annexin V-FITC and incubated for 15 min
incubation on ice in the dark before adding 300 μl of calcium buffer
and acquired using a FACSCanto II flow cytometer (BD Biosciences).
Propidiumidodide (PI) staining
3x105 cells were fixed in 70% ethanol in PBS and stored at -20. Cells
were centrifuged at 3,000 RPM for 7 min then resuspended in Hanks’
solution and incubated at 37 for 30 min before recollecting them
(10,000 RPM, 5 min), and treating with RNase-PI (Amersham) for 15
min and acquired using a FACSCanto II flow cytometer and analysed
using Diva™ software. Cell death induction was determined as the
percentage of cells in sub-G1. Specific apoptosis was calculated as (%
apoptotic cells with treatment - % apoptotic cells without treatment) /
(100 - % apoptotic cells without treatment) x 100, to correct for the
presence of dead cells in the untreated samples. Cell cycle distribution
was determined from the cycling population.
Assessment of cell morphology (apoptotic index)
Cell morphology has been studied and quantified on haematoxylin
and eosin-stained cytospins as described before [10].
Induction of mitotic arrest
Cells were treated with 0.3 µM of the microtubule inhibitors
colcemid and nocodazole (in DMSO; Supplementary Figure 3) for 16 h
before treatment with TRAIL. Alternatively, cells were washed twice
after nocodazole treatment and either treated immediately or released
for 6h to generate cells in G1 phase prior to TRAIL treatment.
Western blot analysis
Cells were harvested by centrifugation, lysed, denatured and
proteins separated and blotted as described before [6]. Blots were
incubated with rabbit polyclonal antibodies against caspase-3 (1:1 000;
Cell Signaling Technologies, Danvers, MA, USA), Mcl-1 (1:1 000; Cell
Signaling Technologies), Cyclin E (1:1 000, Sigma), Cyclin B1 (1:1
000,ThermoScientific),or actin (1:500; Sigma) and mouse monoclonal
antibodies against caspase-8 1C12 (1:1 000; Cell Signaling
Technology), XIAP (1:5 000; Assay Design), cFLIP (1:200 Alexis
Pharmaceutical), Bcl-XL (H-5) (1:200; Santa Cruz) and Bcl-2 (100)
(1:200; Santa Cruz).For detection, appropriate horseradish peroxidase-
conjugated goat secondary antibodies were used. Protein bands were
visualized with SuperSignal® West Pico Chemiluminescent Substrate
(Pierce) or Immobilon western HRP substrate (Millipore) on X-ray
film (Agfa).
Centrifugal elutriation
Enrichment of K562 cells in the different phases of the cell cycle was
achieved using a J-26 XP Beckman elutriation centrifuge with a JE-5.0
rotor equipped with a single-standard 5 ml elutriation chamber
(Beckman Coulter, Inc., Fullerton, CA, USA) and a Masterflex®L/
S®peristaltic pump, model 7523-47 (Cole Parmer). Rotor speed was
maintained at 2,200 RPM at 8°C, and the medium flow-rate was
controlled by a Cole-ParmerMasterflex pump. Cells were equilibrated
in the chamber with a constant flow rate of 15 ml/min. 100 ml
fractions were collected at flow rates increasing from 15 to 60 ml/min.
PI-stained samples from each fraction were analysed by flow
cytometry to determine the enrichment. Cell fractions were seeded at
3x105 cells/ml in 24-well plates and treated with TRAIL immediately.
Statistical analysis was carried out using two-way Anova with
GraphPad Prism.
Statistical analysis
All results presented are the outcome of the minimum of three
independent repeats. Significant differences have been determined
using paired student t-test with a p<0.05 significance threshold.
Results
AraC sensitises K562 cells to TRAIL-induced apoptosis
K562 cells were treated for 24 h or 48 h with 1-5 µM of araC and
induction of cell death measured. Flow cytometric analysis of the sub-
G1 population and AnnexinV staining showed that araC induced up
to 27% apoptosis (Supplementary Figure 1A-1C). Cell cycle analysis
showed that araC decreased the percentage of K562 cells in S phase
and increased the proportion of cells in G2/M consistent with a delay
in S phase progression, and G2/M arrest (Supplementary Figure 1D).
To determine whether the combination of araC and TRAIL have a
stronger cytotoxic effect, cells were treated with a dosage of araC (1-5
μM) for 24 h, followed by treatment with 250 ng/ml of TRAIL for an
additional 24 h (Figure 1A and 1B). TRAIL (250 ng/ml) alone induced
a maximum of 30% apoptosis determined with PI staining (Figure 1A
and 1B) or AnnexinV (E), while pre-treatment with araC resulted in a
dose-dependent increase in TRAIL-induced sub-G1 population (from
32.3 ± 4.8 to 64.0 ± 3.1%; Figure 1A and 1B). Similar results were
gained with AnnexinV staining (Supplementary Figure 1E). Flow
cytometric analysis of cell cycle distribution revealed that the
proportion of cells in G2/M phase decreased after combined araC/
TRAIL treatment (Figure 1C) suggesting that cells in G2/M were being
depleted by the combination treatment.
DDR kinase inhibition sensitises K562 cells to TRAIL
The cell cycle arrest observed after araC treatment suggests DDR
activation. To characterise the effect of DDR protein kinase inhibition
on TRAIL-induced apoptosis we used specific inhibitors of DNA-PK
(NU7441) [11], ATM (KU55933) [12], and Chk1 (UCN-01) [13,14].
Treatment of cells with NU7441 and UCN-01 alone led to a slight
increase of apoptosis as determined by PI staining (Figure 2A), while
KU5933 alone induced apoptosis in 20.8 ± 3.1% of the cells (Figure
2A). When TRAIL was combined with the DDR kinase inhibitors,
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DNA-PK inhibition or Chk1 inhibition resulted in a reduction of
TRAIL-induced apoptosis, while ATM inhibition enhanced it by two-
fold (Figure 2A). Comparable results were obtained after Annexin V
staining (Supplementary Figure 2).
Figure 1: AraC sensitizes K562 cells to TRAIL-induced apoptosis.
K562 cells were treated for 24h with the indicated doses of
cytarabine (araC) followed by 24 h treatment with 250 ng/ml
TRAIL, before being harvested for PI staining. Analysis of PI by
flow cytometry was used to determine the percentage of Sub-G1
cells in the cycling population. A) Flow cytometry histograms from
a representative experiment for determination of the percentage of
Sub-G1 cells after combination treatment with araC and TRAIL. B)
Effect of combination treatment of araC and TRAIL on apoptosis
induction. Data represent the average % of cell death induced ±
STD. C) Effect of combination treatment with araC and TRAIL on
cell cycle distribution. Data represent the mean percentage of cells
± STD.
Cell cycle analysis showed that NU7441 increased the percentage of
cells in G1, and a decrease in S phase, while inhibition of Chk1 led to
an increase in S phase and a decrease in G2/M. Administration of
TRAIL did not alter this trend (Figure 2B). The effect of KU5933 on
cell cycle distribution was more pronounced (Figure 2B). It led to a
slight decrease of cells in which was associated with an increase of cells
in G2/M from 21.7 ± 2.9% to 32.7 ± 5.2% (Figure 2B, -TRAIL series).
However, when KU5933was combined with TRAIL, the proportion of
cells in G2/M decreased from 32.7 ± 5.2% to 23.2 ± 5.1%, indicating
that cells in G2/M may be main contributors to the increase in cell
death observed in the combination treatment (Figure 2A). The
synergistic cytotoxic effect of both AraC or KU5933 was associated
with significantly reduced cFLIP expression and enhanced processing
of both pro-caspase-8 and pro-caspase-3, and cleavage of cFLIP long
(43kDa fragments on the Western blots) (Figure 2C) indicating
enhanced DR4/DR5 activation.
Treatment of cells in mitosis sensitises K562 cells to TRAIL
To test whether cells in G2/M are more sensitive to TRAIL, cells
were arrested in mitosis using 0.3 µM nocodazole or 0.1 µM colcemid
for 16 h and then treated with TRAIL for 24 h. (Supplementary Figure
3). Themicrotubule disrupting drugs arrested up to 80% of cells in
mitosis and induced 14.7% and 7.9% cell death, respectively.
Combination of nocodazole or colcemid with TRAIL resulted in
asynergistic, up to 7-fold increase in apoptosis (Supplementary Figure
3A and 3B).
To further investigate whether cell cycle phase affected TRAIL
sensitivity, cells were released from nocodazole-induced mitotic arrest
for 6 h to generate cells in G1 phase (Supplementary Figure 3C).
Interestingly, treatment with TRAIL led to a 5- and 7-fold increase in
apoptotic cells in G1-andM-phase enriched populations, respectively
(Figure 2D). It has to be noted that TRAIL-induced apoptosis was
higher when the mitotic block was sustained by the continued
presence of nocodazole or colcemidin the media (Supplementary
Figure 3B and Figure 2D).
In order to test whether the prolonged mitotic arrest or unrelated
effects of nocodazole rendered the cells hypersensitive to TRAIL [15],
we fractionated asynchronous (AS) cells into fractions of cells in the
different phases of the cell cycle by using centrifugal elutriation
(Figure 3Aand 3B). Fractions of cells enriched in G1, G1/S, S and
G2/M phases were then treated with 50 nM TRAIL for 24 h and
induction of cell death measured (Figure 3C). TRAIL sensitivity was
higher in the fractions enriched for cells in G1 (24.1 ± 3.3%) and G2/M
(23.0 ± 2.0%) than in the G1/S fraction (13.1 ± 5.1%), S phase (12 ±
8%) or S/G2M phase (13.3 ± 8.7%; Figure 3C and Figure 2D).
The expression level of the key components of the TRAIL apoptotic
machinery, namely Bcl-2, Bcl-XL, Mcl-1, Bid, XIAP, cFLIP, were also
analysed in the elutriation fractions (Figure 3D). As controls of
population purity, the level of cyclins E and B1, key regulators of the
G1/S and G2/M phases, respectively, were included. In the AS and G1
populations the level of cyclin E is low, consistent with a majority of
cells being in the G0/G1 phase, in G1/S population the level of cyclin E
peaked before starting to decrease gradually in the populations
enriched for cells in S, S/G2 and G2/M. In the AS and the G1
populations the level of cyclin B1 was low, again consistent with the
majority of the cells being in G0/G1 phase. The level of cyclin B1
increased in the population enriched for S phase and peaked in the
populations enriched in S/G2 and G2/M phase (Figure 3D),
confirming the enrichment for the cell cycle phases (Figure 3A and
3B). When looking at proteins of the apoptotic machinery, Bcl-2, Bcl-
XL, Mcl-1, Bid, and XIAP showed no cycle-dependent expression. On
the contrary, the expression of cFLIP oscillated synchronously with
cell cycle progression, with low levels of cFLIP in the populations
enriched for cells in G1 and the G2/M phases (Figure 3B), the phases
where the cells showed the highest TRAIL sensitivity (Figure 3C).
Discussion
K562 cells are derived from a CML patient with blast crisis showing
characteristics of early erythroid cells and expression of the major red
cell sialoglycoprotein, glycophorin [8]. Probably through expression of
the Bcr-Abl fusion protein, K562 cells are quite drug resistant, and was
here used as a model for TRAIL-resistant erythroleukemia [8].
Here we explored the utility of the death ligand cytokine TRAIL as a
novel treatment option. We found that araC has a synergistic cytotoxic
effect with TRAIL. Similar results have been reported in other cancer
types. For example, cisplatin [16], etoposide [16,17] doxorubicin [17],
and irradiation [18] have been shown to sensitise leukemia or
gliomacells to TRAIL.
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Figure 2: Inhibition of the DDR kinase ATM sensitizes K562 cells
to TRAIL-induced apoptosis. K562 cells were treated for 24h with
specific inhibitors of DDR kinases [DNA-PK (NU7441, 10 µM)
ATM (KU-55933, 10 µM), and Chk1 (UCN-01, 100 nM)] followed
by 24h treatment with 250 ng/ml TRAIL, before being harvested for
PI staining. Analysis of PI by flow cytometry was used to determine
the percentage of cells in Sub-G1 and the percentage of cells in each
phase of the cell cycle from the cycling population. Proteins were
extracted for western blotting. A) Effect of combination treatment
with DDR inhibitors and TRAIL on apoptosis induction
determined using PI staining. B) Effect of combination treatment
with DDR inhibitors and TRAIL on cell cycle distribution of the
cycling population. C) Effect of combination treatment of araC (5
µM) and TRAIL and of ATM inhibitor (KU55933) on the
expression of cFLIP, caspase-8, cleaved caspase-8 and cleaved
caspase-3. D) Cells in G1 and G2/M are more sensitive to TRAIL-
induced apoptosis. K562 cells were mock-treated (AS; white bars)
or treated with 0.3 µM nocodazole for 16 h to induce arrest in
mitosis. Nocodazole was then removed and M-phase cells were
either treated with TRAIL (black bars) or allowed to re-enter the
cell cycle for 6 h, and then treated with TRAIL (grey bars, enriched
population in G1). The graphs show the mean of three independent
experiments ± STD.
The cytotoxic effects of araC are related to its ability to be
incorporated into DNA and induce replication fork stalling, which
induces S-phase delay and G2/M arrest and triggering the DNA
damage response pathway [19-22]. In agreement with another study,
where TRAIL has been reported to cause rapid activation of ATM- and
DNA-PK-dependent phosphorylation of H2AX and Chk2 [23], we
also found that while inhibition of DNA-PK or Chk1 did not influence
TRAIL-induced apoptosis, inhibition of ATM also sensitise K562 cells
to TRAIL-induced apoptosis.
Figure 3: Higher TRAIL sensitivity of cells in G1 and G2/M phase
of the cell cycle K562 cells were subjected to centrifugal elutriation
to obtain fractions of cells enriched in different phases of the cell
cycle before treatment with TRAIL (50 nM). Cells were stained with
PI and analysed by flow cytometry, and proteins were extracted for
western blotting. A) Representative histograms of K562 cells before
(AS) and after centrifugal elutriation. B) Cell cycle distribution of
K562 cells before (AS) and after centrifugal elutriation. C) TRAIL
sensitivity of an asynchronous population (AS) and fractions of
cells enriched in G1, G1/S, S, S/G2M and G2/M treated with 25
ng/ml TRAIL. *p<0.05; ***p<0.001. D) Expression of key
components of the apoptotic machinery and of two components of
the cell cycle.
The increased TRAIL-sensitivity after ATM inhibition could result
from down regulation of c-FLIP as previously reported in melanoma
cells [24], and the BH3-only protein Bid has also been shown to be a
target of ATM and to control cellular fate in response to DNA damage
[25,26]. By connecting death receptor signalling to the mitochondrial
amplification loop of the intrinsic pathway [27], Bid could play a role
in the sensitisation to TRAIL observed after both araC treatment and
ATM inhibition.
We found that cells in the G2/M phase were more sensitive to
TRAIL and arresting the cells in G2/M or enriching the culture in
mitosis or in G1 using elutriation led to sensitisation to TRAIL. We
found that cFLIP has an oscillating expression during the cell cycle
with highest expression in G1-S transition and S phases and low
expression during G2/M and G1. This is in agreement with the
reported JNK-dependent proteasome-mediated decrease in c-FLIP in
G2/M [28]. Similarly, the study by Gascoigne found that the apoptotic
threshold gradually reduces during prolonged mitosis [29]. The
observation that the extent of sensitisation was lower when the mitotic
block was removed compared to when the block was sustained
supports a role for prolonged mitotic arrest in the increased sensitivity
of K562 cells to TRAIL-induced apoptosis [28], rather than the
abrogation of the checkpoint [30].
Similar to our results, Ivanov and colleagues observed that ATM
inhibition led to G2/M arrest and sensitised cells to TRAIL-induced
apoptosis [24]. The study showed that gamma-irradiation-mediated
ATM activation led to STAT3-driven cFLIP induction and TRAIL
resistance. Inhibition of ATM blocked cFLIP induction and sensitised
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melanoma cells to TRAIL, highlighting the multifaceted role of ATM
in DNA repair control and our still incomplete understanding of cell
fate decision control in response to DNA damage.
Overall, we show that in the G1 or G2/M phases of the cell cycle;
erythroid leukemia cells become sensitive to TRAIL-induced
apoptosis. This sensitivity can be also achieved and intensified by
arresting the cells in G2/M. Further studies would be necessary to
determine if the increased sensitivity to TRAIL was due to cFLIP down
regulation in G2/M. To translate these findings into clinical use,
studies on primary erythroleukemia cells will need to be carried out.
Importantly, these results warrant further studies into exploring the
efficacy of TRAIL treatment with agents that disturb cell cycle
progression, such as cyclin-dependent kinase inhibitors [31].
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